Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

by Alings, M., Anand, S.S, Avezum, A., Bhatt, D.L, Bosch, J., Branch, K.R.H, Commerford, P.J, COMPASS Investigators, Connolly, S.J, Cook Bruns, N., Dagenais, G.R, Dans, A., Diaz, R., Dyal, L., Eikelboom, J.W, Ertl, G., Felix, C., Fox, K.A.A, Guzik, T., Hart, R.G, Hori, M., Kakkar, A., Keltai, M., Kim, J.-H, Lanas, F., Leong, D., Lewis, B.S, Liang, Y., Lonn, E.M, Lopez-Jaramillo, P., Maggioni, A.P, Metsarinne, K., Moayyedi, P., Muehlhofer, E., O'Donnell, M., Parkhomenko, A.N, Piegas, L.S, Pogosova, N., Probstfield, J., Ryden, L., Shestakovska, O., Steg, P.G, Störk, S., Tonkin, A.M, Torp-Pedersen, C., Verhamme, P.B, Vinereanu, D., Widimsky, P., Yusoff, K., Yusuf, S., Zhu, J.
Published 2019